1.Study of current situations of economic toxicity and associated factors in hematological malignancies patients
Jinlian LI ; Yaping HUANG ; Zijin WU ; Lingling TIAN ; Chupin CEN ; Shan HUANG
China Modern Doctor 2025;63(11):35-38
Objective To investigate the current situations of economic toxicity in hematological malignancies patients,and explore it's correlation with quality of life and psychological resilience.Methods A total of 135 hematological malignancies patients admitted in Sun Yat-sen Memorial Hospital,Sun Yat-sen University from December 2022 to October 2023 were selected as subjects.Patients were surveyed by using general information and disease-related information questionnaires,comprehensive scores for financial toxicity,European organization for research and treatment of cancer core questionnaire,connor-davidson resilience scale,social support rating sale.Correlation analysis was performed by using the Pearson method.Multiple linear regression was used to analyze the factors of economic toxicity after controlling for confounding factors.Results Economic toxicity score of 135 hematological malignancies patients was(15.95±0.84)points,of which 82.2%of them had economic toxicity.It was positively correlated with functional quality of life(r-0.464,P=<0.001)and psychological resilience(r=0.232,P=0.007),and negatively correlated with symptomatic psychological quality(r=-0.440,P<0.001).Multiple linear regression analysis showed that quality of life,knowledge of the treatment cost,course of treatment,patient personality and have no second caregiver were influencing factors of economic toxicity of hematological malignancies(P<0.05).Conclusion Hematological malignancies patients have a higher level of economic toxicity,which can affect their quality of life and psychological resilience.
2.Study of current situations of economic toxicity and associated factors in hematological malignancies patients
Jinlian LI ; Yaping HUANG ; Zijin WU ; Lingling TIAN ; Chupin CEN ; Shan HUANG
China Modern Doctor 2025;63(11):35-38
Objective To investigate the current situations of economic toxicity in hematological malignancies patients,and explore it's correlation with quality of life and psychological resilience.Methods A total of 135 hematological malignancies patients admitted in Sun Yat-sen Memorial Hospital,Sun Yat-sen University from December 2022 to October 2023 were selected as subjects.Patients were surveyed by using general information and disease-related information questionnaires,comprehensive scores for financial toxicity,European organization for research and treatment of cancer core questionnaire,connor-davidson resilience scale,social support rating sale.Correlation analysis was performed by using the Pearson method.Multiple linear regression was used to analyze the factors of economic toxicity after controlling for confounding factors.Results Economic toxicity score of 135 hematological malignancies patients was(15.95±0.84)points,of which 82.2%of them had economic toxicity.It was positively correlated with functional quality of life(r-0.464,P=<0.001)and psychological resilience(r=0.232,P=0.007),and negatively correlated with symptomatic psychological quality(r=-0.440,P<0.001).Multiple linear regression analysis showed that quality of life,knowledge of the treatment cost,course of treatment,patient personality and have no second caregiver were influencing factors of economic toxicity of hematological malignancies(P<0.05).Conclusion Hematological malignancies patients have a higher level of economic toxicity,which can affect their quality of life and psychological resilience.
3.Effect and mechanism of Sitravatinib combined with Niraparib on proliferation,apoptosis and autophagy in mucosal melanoma cell lines
Zijin HU ; Yan KONG ; Xiaowen WU ; Qian GUO ; Jun GUO
Basic & Clinical Medicine 2024;44(3):295-302
Objective To investigate the effect of anti-angiogenic drug Sitravatinib combined with poly(adenosine diphosphate[ADP]-ribose)polymerase inhibitor(PARPi)Niraparib on mucosal melanoma cell lines and its possible mechanism.Methods The CCK8 assay was used to detect the maximal half inhibitory concentration(IC50)of Sitravatinib and Niraparib targeting at mucosal melanoma(MM)cell lines.CompuSyn was used to detect the Combination Index(CI)in different concentrations of the two drugs.Flow cytometry was used to detect the effect of drugs on cell apoptosis.Colony formation assay was used to detect the effect of drugs on cell proliferation.Western blot was used to detect the protein expressions and RT-qPCR was used to detect mRNA expression.Results CI values was respectively 0.19 and 0.15 for Sitravatinib(2 μmol/L)in combination with Niraparib(20 μmol/L)in a human vaginal maligant melanoma cell line(HMVII)and a metastasis inguinal lymph node of vulvar malignant melanoma cell line(GAK).Compared with the control group and single-drug groups,the cell proliferation of the combination group was significantly reduced(P<0.05 or P<0.01 or P<0.001).The cell apoptosis rate was signifi-cantly increased(P<0.01 or P<0.001).The protein and mRNA expression of apoptosis-related biomarkers signifi-cantly increased(P<0.001);In addition,the protein and mRNA expression of cell autophagy biomarkers signifi-cantly increased(P<0.01 or P<0.001).The protein expression of DNA damage marker significantly increased.Moreover,compared with the control group,The expression of radiation sensitive protein 51(RAD51)recombinase in the Sitravatinib single-drug group and combination group significantly reduced.As the dose of Sitravatinib gradu-ally increased up to 2 μmol/L,the protein and mRNA expression of RAD51 both significantly reduced(P<0.05 or P<0.01),the mRNA expression of BRCA1 and BRCA2 also significantly reduced(P<0.05 or P<0.01 or P<0.001).Conclusions Sitravatinib combined with Niraparib inhibits the proliferation of mucosal melanoma cells,induces cell apoptosis and promotes autophagy.The mechanism is potentially related to the inhibition of ho-mology-dependent recombination repairs(HRR).
4.Global burden and trends of lung cancer incidence and mortality.
Chao LI ; Shaoyuan LEI ; Li DING ; Yan XU ; Xiaonan WU ; Hui WANG ; Zijin ZHANG ; Ting GAO ; Yongqiang ZHANG ; Lin LI
Chinese Medical Journal 2023;136(13):1583-1590
BACKGROUND:
Lung cancer has been the leading cause of cancer-related deaths worldwide for many years. This study aimed to investigate the global patterns and trends of lung cancer.
METHODS:
Lung cancer incidence and mortality were derived from the GLOBOCAN 2020 database. Continuous data from Cancer Incidence in Five Continents Time Trends were used to analyze the temporal trends from 2000 to 2012 using Joinpoint regression, and average annual percent changes were calculated. The association between the Human Development Index and lung cancer incidence and mortality was assessed by linear regression.
RESULTS:
An estimated 2.2 million new lung cancer cases and 1.8 million lung cancer-related deaths occurred in 2020. The age-standardized incidence rate (ASIR) ranged from 36.8 per 100,000 in Demark to 5.9 per 100,000 in Mexico. The age-standardized mortality rate (ASMR) varied from 32.8 per 100,000 in Poland to 4.9 per 100,000 in Mexico. Both ASIR and ASMR were approximately twice higher in men than in women. The ASIR of lung cancer showed a downward trend in the United States of America (USA) between 2000 and 2012, and was more prominent in men. The age-specific incidence rates of lung cancer for ages of 50 to 59 years showed an upward trend in China for both men and women.
CONCLUSIONS
The burden of lung cancer is still unsatisfactory, especially in developing countries like China. Considering the effectiveness of tobacco control and screening in developed countries, such as the USA, there is a need to strengthen health education, accelerate the establishment of tobacco control policies and regulations, and improve early cancer screening awareness to reduce the future burden of lung cancer.
Male
;
Humans
;
Female
;
United States
;
Middle Aged
;
Incidence
;
Lung Neoplasms/epidemiology*
;
Linear Models
;
China/epidemiology*
5.Research and practice of diagnosis and improvement system in medical practice teaching
Mochang QIU ; Jian WU ; Zijin XU
Chinese Journal of Medical Education Research 2020;19(3):287-291
Practice, an important part of medical teaching happened in hospitals, is difficult to be included in the diagnosis and improvement system of schools. Therefore, Jiangxi medical college has established the "five-point and seven-line" diagnosis and improvement system in practice teaching and promoted its implementation according to the idea of "emphasis on key points, point to string transformation, problem-oriented approach, continuous improvement, comprehensive promotion and stratified diagnosis and reform". Through two years' practice, some achievements have been made in the practice teaching management, the improvement of the basic knowledge of interns, the enhancement of teaching and learning consciousness and so on. The achievements have further promoted the cultivation of the concepts of diagnosis and reform of both schools and hospitals, and facilitated the efficiency of practice management and the quality of practice teaching.
6.Construction of diagnosis and improvement system for training interns through a method focusing on "five elements and seven ways of giving feedback"
Mochang QIU ; Jian WU ; Zijin XU
Chinese Journal of Medical Education Research 2018;17(3):269-272
At present,diagnosis and improvement of teaching quality in higher vocational colleges mainly depends on the internal quality assurance system shaped by "five vertical,five horizontal and one platform".Practical teaching is of great importance to medical education.As its teaching quality is mainly generated from the hospitals which are difficult to be integrated with the existing internal quality assurance system.This article tries to build a diagnosis and improvement system for training interns through a method focusing on "five elements and seven ways of giving feedback" on the basis of the in-depth analysis of factors generating the quality of intern training.This system aims to continuously ensure the quality of interns training via supplementing and perfecting the existing internal quality system of medical colleges.
7.Albumin bound paclitaxel for the treatment of retreatment advanced non-small-cell lung cancer
Lin LI ; Ping ZHANG ; Hui WANG ; Zijin ZHANG ; Xiaonan WU
Cancer Research and Clinic 2016;28(5):325-327
Objective To observe the efficacy and safety of albumin bound paclitaxel in the treatment of retreatment advanced non-small-cell lung cancer (NSCLC).Methods Retreatment NSCLC patients failed from first line regimen or beyond were treated with albumin bound paclitaxel weekly by intravenous dose of 130 mg/m2 on day 1 and day 8,with a 21-day cycle.Efficacy was evaluated every two cycles and side effects were observed during each cycle.Results None of 69 patients achieved complete remission (CR),15 patients (21.7 %) achieved partial remission (PR),and 23 patients (33.4 %) achieved stable disease (SD).Objective response rate (ORR) was 21.7 %,disease control rate (DCR) was 55.1%,and progress free survival (PFS) time was 3.8 months.Efficacy was not correlated with gender,age,histology and lines of previous treatment (all P > 0.05).Main adverse reactions included neutropenia,alopccia and neurotoxicity,which were all tolerable.Conclusion Weekly albumin bound paclitaxel is effective and well tolerated in the treatment of retreatment advanced NSCLC,which can be considered as the second line or beyond regimen.

Result Analysis
Print
Save
E-mail